Aurigene provides Research Cell Bank services designed to establish a consistent and traceable cell source for discovery and early development programs. Research cell banks serve as the foundational material used in clone evaluation, process development studies, and analytical characterization during the early phases of biologics development.
Our research cell banking services are integrated with Aurigene’s cell line development and upstream development platforms. The workflow supports pool generation, monoclonal screening, stability evaluation, and cryopreservation, ensuring that research programs are supported by reproducible and well-documented cell sources.

Research cell banks at Aurigene are generated within a comprehensive cell line development environment designed to support early biologics discovery and development programs. The platform supports widely used mammalian expression systems and integrates clone generation, evaluation, and development workflows that help establish consistent and traceable cellular sources for research programs.
Aurigene applies a structured screening framework to evaluate candidate clones before research cell banking. This stage focuses on identifying cell populations that demonstrate suitable productivity, growth behavior, and expression stability under controlled culture conditions.
Once suitable clones are selected, research cell banks are prepared through controlled cryopreservation workflows designed to maintain cell viability and reproducibility across development studies. The infrastructure also supports secure storage and organized management of cryovial inventories.
Research cell banks established within this platform serve as consistent starting material for multiple development activities. By preserving a stable cell source early in development, research teams can improve comparability across experiments and support smoother progression of biologics programs.
Research cell banking activities operate within a digitally enabled quality environment that supports traceability, documentation control, and consistent handling of research materials throughout development programs.
Research cell banking is supported by Aurigene’s broader platform spanning cell line development, upstream process development, analytical characterization, formulation development, and manufacturing.
Automated monoclonal generation and clone evaluation workflows help identify productive and stable clones suitable for early development programs.
Large-scale liquid nitrogen storage capacity supports reliable preservation and availability of research cell banks.
Aurigene’s digital systems support documentation control, data integrity, and operational transparency across development activities.
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
April 21, 2026
The 6,6a-dihydro-5H-isoquinolino[2,3-a]quinazoline-5,7,12-trione (DIQT) derivatives (that belong to the quinazoline-based fused tetracyclic class of compounds) though known in the literature, their biological properties have not been explored previously. In the current study, we have explored the phosphodiesterase 4B (PDE4B, an important target for the identifica...
Read MoreJanuary 31, 2025
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read MoreJanuary 31, 2025
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market